{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:59:09Z","timestamp":1790168349998,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106858","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:19:38Z","timestamp":1784330378000},"page":"106858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis?"],"prefix":"10.1016","volume":"10","author":[{"given":"Fanny","family":"Lemari\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Galinat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jaouen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Pan-Petesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Herbreteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanig","family":"Civi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La\u00ebtitia","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne-Corentin","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-7287","authenticated-orcid":false,"given":"Jean Christophe","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106858_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106858_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106858_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.rpth.2026.106858_bib4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1055\/s-0040-1720979","article-title":"Hemorrhage in essential thrombocythemia or polycythemia vera: epidemiology, location, risk factors, and lessons learned from the literature","volume":"121","author":"Nicol","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib5","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1055\/a-1849-8477","article-title":"Hemorrhages in polycythemia vera and essential thrombocythemia: epidemiology, description, and risk factors\u2014learnings from a large cohort","volume":"122","author":"Nicol","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s12185-023-03650-7","article-title":"Prediction of major bleeding events in 1381 patients with essential thrombocythemia","volume":"118","author":"Stuckey","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106858_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bjh.18322","article-title":"Practical management of the haemorrhagic complications of myeloproliferative neoplasms","volume":"199","author":"Jones","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106858_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2006-949664","article-title":"The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106858_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/hematology.2019001318","article-title":"From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms","volume":"2019","author":"Stein","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2026.106858_bib10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3390\/cancers12071746","article-title":"Essential thrombocythemia and acquired von Willebrand syndrome: the Shadowlands between thrombosis and bleeding","volume":"12","author":"Awada","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rpth.2026.106858_bib11","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3324\/haematol.2020.255117","article-title":"Acquired von Willebrand syndrome: focused for hematologists","volume":"105","author":"Franchini","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106858_bib12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/jth.15717","article-title":"Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia","volume":"20","author":"Kubo","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib13","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jth.12967","article-title":"Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count","volume":"13","author":"Lancellotti","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106858_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jth.12964","article-title":"Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH","volume":"13","author":"Bod\u00f3","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.20452\/pamw.3211","article-title":"Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients","volume":"125","author":"Mital","year":"2015","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.rpth.2026.106858_bib17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.thromres.2015.07.029","article-title":"Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera\u2014retrospective analysis of 142 consecutive cases","volume":"136","author":"Mital","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106858_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","article-title":"Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera","volume":"41","author":"Rottenstreich","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rpth.2026.106858_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5045\/br.2023.2022218","article-title":"Acquired von Willebrand syndrome in patients with Philadelphia-negative myeloproliferative neoplasm","volume":"58","author":"Song","year":"2023","journal-title":"Blood Res"},{"key":"10.1016\/j.rpth.2026.106858_bib20","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1055\/a-1806-9972","article-title":"HemosIL VWF:GPIbR assay has a greater sensitivity than VWF:RCo technique to detect acquired von Willebrand syndrome in myeloproliferative neoplasms","volume":"122","author":"Laporte","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.rpth.2026.106858_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15647","article-title":"A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: a British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106858_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.106858_bib24","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00277-014-2224-8","volume":"93","author":"Kreher","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rpth.2026.106858_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.thromres.2022.08.002","article-title":"Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia","volume":"218","author":"Janjetovic","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106858_bib26","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106858_bib27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib28","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00277-016-2826-4","article-title":"Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey","volume":"96","author":"Koren-Michowitz","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rpth.2026.106858_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hon.2903","article-title":"Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis","volume":"39","author":"Trotti","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.rpth.2026.106858_bib36","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ejh.13866","article-title":"von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts","volume":"109","author":"Iizuka","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2026.106858_bib31","doi-asserted-by":"crossref","DOI":"10.1063\/1.4833975","article-title":"Hematocrit and flow rate regulate the adhesion of platelets to von Willebrand factor","volume":"7","author":"Chen","year":"2013","journal-title":"Biomicrofluidics"},{"key":"10.1016\/j.rpth.2026.106858_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/jth.14360","article-title":"Red blood cells: the forgotten player in hemostasis and thrombosis","volume":"17","author":"Weisel","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2007-05-093021","article-title":"Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress","volume":"111","author":"Shim","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106858_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exphem.2017.02.001","article-title":"The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera","volume":"50","author":"Falchi","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1016\/j.rpth.2026.106858_bib35","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617 F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms","volume":"111","author":"Etheridge","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2026.106858_bib37","series-title":"Scientific and Standardization Committee Communication Scientific Report of the Registry on acquired von Willebrand syndrome: recommendations for diagnosis and management","author":"Federici","year":"2000"},{"key":"10.1016\/j.rpth.2026.106858_bib38","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/hae.14648","article-title":"Acquired von Willebrand syndrome and lymphoid neoplasms: a review of malignancy management, and propositions of practical recommendations","volume":"28","author":"Nicol","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106858_bib39","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/jth.14319","article-title":"Clinically relevant differences between assays for von Willebrand factor activity","volume":"16","author":"Boender","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102143","article-title":"Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: considerations based on geography and resources","volume":"7","author":"Favaloro","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib41","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jtha.2023.12.024","article-title":"Discrepant low von Willebrand factor activity results on the ACL TOP analyzer are frequent in unselected patients with myeloproliferative neoplasms and show no correlation with high-molecular-weight multimer loss or bleeding phenotype","volume":"22","author":"Noye","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106858_bib43","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106858_bib44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/rth2.12315","article-title":"Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia","volume":"4","author":"Sacco","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106858_bib45","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/bloodadvances.2024013777","article-title":"Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis","volume":"8","author":"Venkat","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106858_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2016.04.006","article-title":"Multiple electrode aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance","volume":"142","author":"Gillet","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106858_bib47","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/09537104.2017.1361018","article-title":"Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms","volume":"29","author":"Perrier-Cornet","year":"2018","journal-title":"Platelets"},{"key":"10.1016\/j.rpth.2026.106858_bib48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.thromres.2010.06.014","article-title":"Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry","volume":"126","author":"Robier","year":"2010","journal-title":"Thromb Res"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:59:05Z","timestamp":1790164745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926035168"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106858","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis?","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106858"}}